MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML

Leukemia and Lymphoma

Volumn 40, Issue 5-6, 2001, Pages 613-623

  Baldus, C ^a   Fietz, T ^a   Rieder, H ^a   Schwartz, S ^a   Thiel, E ^a   Knauf, W ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Acute myeloid leukemia; Clinical outcome; Fluorescence in situ hybridization; Multidrug resistance

Indexed keywords

ANTILEUKEMIC AGENT; CD14 ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; HLA DR ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; LACTATE DEHYDROGENASE; LUNG RESISTANCE PROTEIN; MEMBRANE PROTEIN; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE; STEM CELL FACTOR RECEPTOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERPHASE; LEUKEMIA REMISSION; MONOSOMY 7; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; TRISOMY 8;

EID: 0035051187     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097659     Document Type: Article

References (51)

1. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia
2. Therapy-related leukemia and myelodysplastic syndrome clinical, cytogenetic, and prognostic features
3. Chromosomal aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
4. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
5. Pharmacologic approaches to reversing multidrug resistance
6. Molecular cytogenetics of multiple drug resistance
7. Detection of multidrug resistance markers, P-glycoprotein and mdr-1 mRNA, in human leukemia cells
8. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
9. Quantitative acute leukemia cytogenetics
10. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
11. Clinical significance of cytogenetics in acute myeloid leukemia
12. Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemia: Evidence for a novel critical locus
13. More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity?
14. The significance of trisomy 8 in de novo acute myeloid leukemia: The accompanying chromosome aberrations determine the prognosis
15. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization
16. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
17. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias
18. Chemotherapy intensity and long term outcome in AML
19. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia
20. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources
21. Correlation of multidrug resistance (mdr1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant mdr-/efflux+ and mdr+/efflux- cases
22. Correlation of P-glycoprotein expression and function in childhood acute leukemia: A children's cancer group study
23. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines
24. Nonparametric estimation from incomplete observation
25. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay
26. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (mdr1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
27. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the southwest oncology group leukemia research program
28. Clinical relevance of drug resistance genes in malignant diseases
29. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia
30. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II alpha) in 57 newly diagnosed acute myeloid leukemias
31. Lack of correlation between multi-drug resistance expression and clinical response to chemotherapy in patients with acute myeloid leukemia
32. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
33. Multidrug resistance in leukemias and its reversal
34. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia
35. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
36. P-glycoprotein expression in acute myeloid leukemia blast cells at diagnosis predict response to chemotherapy and survival
37. Multidrug resistance in acute myeloid leukemia with inversion in chromosome 16 or FAB M4Eo subtype
38. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
39. 2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
40. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
41. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
42. Minimally differentiated acute myeloid leukemia (AML-M0): A distinct clinic-biologic entity with poor prognosis
43. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
44. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
45. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia
46. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
47. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
48. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases
49. Combination of classical and interphase cytogenetics to investigate the biology of myeloid disorders: Detection of masked monosomy 7 in AML
50. Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization
51. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry